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CERCEK and Cercek (1975, 1977) report-
ed that peripheral lymphocytes from
patients with malignant disease showed
specific changes in the 'structuredness of
the cytoplasmic matrix' (SCM) after incu-
bation with cancer basic protein (CaBP).
The structuredness (micro-viscosity) ofthe
cytoplasm is measured by the "index of
polarization" (P) of the light from fluore-
scein molecules stimulated to fluorescence
by linearly polarized blue light while
inside the test lymphocytes. Reaction with
an antigen lowers the value ofP. Lympho-
cytes from non-malignant donors react
in a similar way when incubated with
phytohaemagglutinin (PHA) but retain
their normal unstimulated P when incuba-
ted with CaBP. The magnitude ofthe ratio
P with CaBP/P with PHA is therefore
less than unity for lymphocytes from
malignant subjects, and greater than unity
for non-malignant subjects. This ratio is
designated "RRScM' and acts as an
index of the presence or absence of
malignant disease. By using antigens
extracted from "pure" tumours, the re-
sponse is claimed to be site-specific. Unlike
the previously reported MEM response,
the change in structuredness fades soon
after removal of the tumour, thereby
raising the important possibility of a site-
specific in vitro test which could be used
for both detection and monitoring of can-
cer.
Experience with the macrophage elec-
trophoretic mobility (MEM) test had
shown that a successful technique for the
detection of malignant disease must be
consistently reproducible in a routine
clinical laboratory, and free from sub-
jective interpretation (Pritchard et al.,
1973, 1976). Ideally, the reproducibility of
a proposedtechnique should be established
before embarking on a definitive evalua-
tion by means ofa clinical trial. This paper
reports our progress towards the limited
goal ofestablishing areproducible response
from the SCM technique when applied to
two particular groups, healthy controls
and patients with histologically proved
cancer. A much more extensive series with
a wider range of subjects and antigens,
measured blind with appropriately match-
ed controls, would be needed to confirm the
value ofthe test as a method for detecting
and monitoring malignant disease under
clinical conditions.
In our early experiments the original
protocol ofCerceketal. (1974) wasfollowed
closely, butwe were unable to demonstrate
a reproducible lymphocyte response to
antigen. This was primarily due to inade-
quatesensitivityinthespectrophotometer.
All later measurements used a more sensi-
tive machine (Perkin-Elmer MPF 4). This
produced a considerable improvement in
the measurement of SCM changes in
lymphocytes from non-malignant donors
in response to PHA stimulation (Fig. 1)
where only 3/40 controls failed to respondJ. A. V. PRITCHARD AND W. H. SUTHERLAND
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FIG. 1. Distribution of SCM response
(RRscM) of lymphocytes from healthy
donors (controls) andl patients with
malignant disease.
to PHA (Wellcome Reagent Grade-
diluted 1: 5). However, 41/80 of the malig-
nant-disease group also showed a response
to PHA, contrary to the results of Cercek
et al. (1974), in which lymphocytes from
patients with malignant disease did not
respond to PHA in the SCM technique.
At this point in our experiments it
became evident that the SCM response
of lymphocytes was critically dependent
on the density of the gradient used to
separate them from whole blood. The
effect of small changes in the gradient
density on the reduction of the index of
polarization (P) is shown in Fig. 2 for
control lymphocytes responding to PHA.
Maximum reduction occurs at a gradient
density of 1-081. In order to hold the
gradient density sufficiently close to this
critical value for consistent separation of
"SCM-responding" lymphocytes, tempera-
ture should be controlled in the centrifuge
to ± 1°C throughout the separation. Since
1-081
FIG. 2. Effect ofgradient density onlympho-
cyte response to PHA as measured by
reduction of the index of polarization (P).
adequate control was not possible in the
centrifuge usedfor the experiments leading
to Fig. 1, it is likely that the poor discri-
mination between the 2 groups was caused
partly by failure to separate the correct
"SCM-responding" subpopulation of lym-
phocytes.
It was also clear from Fig. 1 that the
response of control lymphocytes to PHA
was more consistent than the response of
the malignant group to cancer basic pro-
tein (CaBP). Experience with the MEM
test (Pritchard et al., 1978) had indicated
some problems with the activity of CaBP
prepared by the technique of Dickinson
et al. (1974). The work of Muller et al.
(1975) had shown that some degree of
site specificity could be demonstrated in
the MEM test by using a crude KCI ex-
tract of tumour, and site specificity in the
SCM test had been reported by simple
"baiting" of lymphocytes with tumour
tissue (Cercek and Cercek, 1975). Recently
Takaku et at. (1977) have shown that the
reliability of the SCM response of lympho-
cytes from patients with stomach cancer
can depend upon the quality of the CaBP
extracted from colon-cancer tissue, and
that good discrimination between a cancer
and a non-cancer group can be obtained
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with active antigen. By combining the
experience gained so far, and the detailed
protocol described by Cercek and Cercek
(1977), it was now possible to define more
precisely the steps essential for the opera-
tion of the SCM test. Starting in August
1977 a new series of patients with diag-
nosed cancer was investigated, using a
crude KCI extract ofbreast tumour as anti-
gen, together with a small group ofhealthy
controls drawn from hospital staff. The
sample-handling procedures used in these
most recent experiments are summarized
in the Appendix.
The results are shown in the Table. It is
necessary to establish antigen concentra-
tions and stimulation times by experi-
ment, since preparations can vary con-
siderably in activity and from batch to
batch in the case of PHA. Although the
numbers in the Table are small, they are
sufficient to show that under the limited
conditions of this investigation there is a
difference in the SCM response between
patients with breast cancer and normal
subjects, using the same antigen. In 3
cases (Nos. 10, 14 and 15) response to
breast tumour antigen was not apparent
but neither could response to PHA be
detected. In Case No. 1, removal of the
primary tumour was followed by a de-
crease in the response to breast-tumour
antigen within 48 h, but without restora-
tion of PHA response. This was restored
after the longer periods noted for Cases
20 and 21.
Only one of the controls responded to
the breast antigen extract, and in this
particular instance (No. 47) PHA stimu-
lation caused a reduction in P of 210
from the unstimulated value. Some degree
of tumour-antigen specificity is shown in
Group C of the Table, where response to
breast tumour antigen could not be detec-
ted for patients with tumours of different
anatomical site and histology. However,
most of this group differed from the con-
trols in showing negligible response to
PHA. In the 3 cases where a cancer specific
response was demonstrated (Nos. 25, 26
and 30) there was extensive disease, and it
TABLE.-Response of lymphocytes to breast-
tumour antigen and PHA
A. Breast cancer, tumour
present
B. Breast cancer P/O,
no residual disease
C. Cancer of other sites
Cervix Stage I P/O
Cervix Stage IIb
Cervix Stage Ila
Post R/T
Cervix Stage III
Cervix Stage IlIb
Vulva
Ovary
Bronchus
Bladder (advanced)
Bladder
Oesophagus
Skin S.CC.
D. Controls
Case
no.
I 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
1
(48 h
P/O)
20
(7 days
P/O)
21
(21 days
P/O)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
* But 210% reduction to PHA.
t 12 weeks pregnant.
Age SexRRscm
47 F 0 62
87 F 0 59
37 F 0-84
63 F 0 75
53 F 0 82
76 F 0 74
70 F 0 65
46 F 0 77
51 F 0-69
72 F 1-00
46 F 0-86
44 F 0 90
47 F 0-84
81 F 0-98
46 F 1 -00
51 F 0M81
53 F 0 74
84 F 0 84
67 M 0 81
47 F 0 82
49 F 1-13
42 F 1-40
27
52
76
73
31
78
62
54
75
71
79
73
35
23
18
23
36
56
41
30
47
55
22
27
28
39
54
27
57
27
F
F
F
F
F
F
F
M
M
M
F
M
F
F
F
F
F
M
F
F
F
F
F
F
M
F
F
F
F
F
1*18
1 00
1*00
0-78
0-67
1*00
1 00
1 .00
0 77
1*00
1 .00
1 00
1 *20
1 *26
1 *34
1 *42
1 *82
1 *22
1 *42
1 *21
1 *45
1 *21
1 *08
1 *23
1 *24
0.71*
1 *34
1 *32
1 *46
1*56t
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isreasonable to considersomeformofcross-
reactivity to the relatively crude antigen.
It has been suggested that the technical
difficulties associated with the measure-
ment of SCM are considerable. Our experi-
ence in the past month, following the
successful introduction of a new untrained
technician, suggests that once the para-
meters of the SCM technique have been
established and carefully controlled, the
test can be operated easily.
Although our most recent results sum-
marized in the Table are encouraging, and
provide a limited confirmation of the
results reported by the Cerceks, we repeat
that the value of the test in the detection
and monitoring of malignant disease
requires careful and extensive clinical
assessment. It is important to improve
antigen-extraction procedures, since anti-
gen and PHA variability can markedly
affect the results. At present a limiting
factor is the number of samples that can
be handled. As more antigens become
available, with greater site specificity, and
therefore requiring an increased range of
tests against each blood sample, problems
are likely to arise due to the low yield of
"SCM-responding" lymphocytes.
APPENDIX
Peripheral lymphocytes were isolated
from 10 ml aliquots of heparinized blood,
collectedin Searle LH/10tubes. Thesewere
mixed with 0.1 g carbonyl iron (G.A.F.,
type S.F.) by rotation at 30 rev/min for
30 min at 37°C in a plane tilted 450 from
vertical, with a mid-tube radius of 7 cm.
After mixing, the containers stood at
37°C on a magnet for 10 min, to enhance
sedimentation ofiron particles. The blood,
suitably mixed after sedimentation ofiron,
was equilibrated to the gradient tempera-
ture and carefully layered on to a modified
Ficoll/Triosil gradient (Cercek and Cer-
cek, 1977). During the early experiments
lymphocytes were separated by centrifuga-
tion at 550 g for 20 min (g calculated at
interface) but later investigations showed
that 1100 g for 20 min allowed a more
reproducible separation of "SCM-respond-
ing" lymphocytes. During the separation
the temperature was controlledto maintain
the density at 1 081. Depending on the
batch ofgradient, this required a tempera-
ture in the range 19-25°C.
After separation it was quite common,
especially at 1100 g, to see a faint 'double
band' oflymphocytes. When this occurred
only the top band was collected. In the
absence of a "double band" only lympho-
cytes which "floated" as an indistinct
layer above the gradient layer in the
plasma area were collected. The lympho-
cytes were then washed twice by centrifu-
gation with 0-9% saline, and once with
complete PBS previously warmed to
37°C, before resuspension at a cell density
not exceeding 5 x 106 cells/ml. Cells-were
maintained at 37°C until required.
The fluorescein diacetate (FDA) sub-
strate was at first prepared by the method
of Cercek et al. (1974) but in all later
experiments a modified technique (Cercek
and Cercek, 1977) was used, with acetic
acid (Aristar GradeBDH) asthesolventfor
FDA instead of spectroscopic-grade ace-
tone (Eastman-Kodak Ltd.). Osmolality
and pH of the FDA substrate were care-
fully controlled at 0 330 Osm/kg and 7-4
respectively. In all other aspects of the
technique (care of glassware, choice of
polarizing filters and measurement of the
SCM response) the methods recently
described by Cercek and Cercek (1977)
were closely adhered to.
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